Back to search
Pulmonary Fibrosis Idiopathic Familial
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Pulmonary Fibrosis Idiopathic Familial trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Pulmonary Fibrosis Idiopathic Familial trials you may qualify forThe goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants wi…
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form…
This study aims to improve the understanding of how genes and the environment can influence and cause pulmonary fibrosis. By identifying the presence of genes a…
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose…
Scarring of the lung, termed pulmonary fibrosis (PF), is a chronic, progressive, and usually fatal disorder. While two anti-fibrotic drugs have been approved fo…